We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-14.23%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.99B
AUM Growth
-$1.5B
Cap. Flow
-$539M
Cap. Flow %
-10.81%
Top 10 Hldgs %
44.72%
Holding
159
New
13
Increased
22
Reduced
36
Closed
24

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$47.6M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$33.3M
3
NVRO
NEVRO CORP.
NVRO
+$32.7M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$32.1M
5
PEN icon
Penumbra
PEN
+$31.9M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$104M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$92.4M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$46.5M
4
KOD icon
Kodiak Sciences
KOD
+$44.1M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$37.1M

Sector Composition

Rank Sector Weight
1 Healthcare 81.81%
2 Financials 0.77%
3 Industrials 0.12%
4 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVNO
101
enVVeno Medical
NVNO
$6.94M
$4.98M 0.1%
22,332
– –
DALS
102
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$4.86M 0.1%
500,000
– –
PEAR
103
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$4.68M 0.09%
926,232
– –
SGHT icon
104
Sight Sciences
SGHT
$291M
$4.51M 0.09%
390,000
– –
OBIO icon
105
Orchestra BioMed
OBIO
$228M
$4.46M 0.09%
450,000
– –
NVTA
106
DELISTED
Invitae Corporation
NVTA
$4.42M 0.09%
554,585
-1,030,000
-65% -$10.4M
IMRX icon
107
Immuneering
IMRX
$262M
$4.41M 0.09%
681,051
– –
RLMD icon
108
Relmada Therapeutics
RLMD
$540M
$4.08M 0.08%
+151,350
New +$3.13M
NARI
109
DELISTED
Inari Medical, Inc. Common Stock
NARI
$2.72M 0.05%
+30,000
New +$2.46M
RVNC
110
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.68M 0.05%
+137,514
New +$2.09M
SONX
111
DELISTED
Sonendo, Inc.
SONX
$2.68M 0.05%
668,505
– –
ZY
112
DELISTED
Zymergen Inc. Common Stock
ZY
$2.55M 0.05%
883,332
– –
PRTA icon
113
Prothena Corp
PRTA
$448M
$2.38M 0.05%
65,144
-34,856
-35% -$1.26M
ABOS icon
114
Acumen Pharmaceuticals
ABOS
$152M
$2.33M 0.05%
+596,942
New +$3.25M
TARA icon
115
Protara Therapeutics
TARA
$214M
$1.96M 0.04%
383,526
-38,115
-9% -$200K
DRIO icon
116
DarioHealth
DRIO
$51.9M
$1.92M 0.04%
16,393
– –
LENZ
117
LENZ Therapeutics
LENZ
$179M
$1.66M 0.03%
46,551
-74,891
-62% -$4.69M
RETA
118
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$1.46M 0.03%
+44,475
New +$1.32M
RACE icon
119
Ferrari
RACE
$67.8B
$1.35M 0.03%
6,200
– –
ONCR
120
DELISTED
Oncorus, Inc.
ONCR
$1.34M 0.03%
752,241
-247,571
-25% -$694K
RPID icon
121
Rapid Micro Biosystems
RPID
$102M
$1.29M 0.03%
190,745
-194,948
-51% -$1.44M
MOTS
122
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$648K 0.01%
6,002
– –
NEPT
123
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$445K 0.01%
1,429
-5,754
-80% -$2.61M
RKLY.WS
124
DELISTED
Rockley Photonics Holdings Limited Warrants, each warrant exercisable for one ordinary share at an exercise price of $11.50
RKLY.WS
$425K 0.01%
500,000
– –
BFLY.WS
125
DELISTED
Butterfly Network Inc Warrants
BFLY.WS
$238K ﹤0.01%
233,333
– –
3 4
5
6 7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Perceptive Advisors held 159 positions worth $4.99B, down 23% from $6.49B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors withdrew a net $539M in Q1 2022, closing 24 positions and reducing 36 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $104M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in CinCor Pharma, Inc. Common Stock worth $40.7M.

  • Perceptive Advisors's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 2,319,117 shares worth $40.7M.
  • Perceptive Advisors added most to NEVRO CORP. in Q1 2022, an estimated $32.7M increase.
  • Perceptive Advisors's biggest Q1 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $92.4M.
  • Perceptive Advisors fully exited BioMarin Pharmaceuticals in Q1 2022, selling an estimated $104M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $4.99B portfolio in Q1 2022.
  • Perceptive Advisors opened 13 new positions and closed 24 in Q1 2022.
  • Perceptive Advisors's portfolio value fell 23% quarter-over-quarter to $4.99B.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.